These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22305775)

  • 1. Metabolic syndrome and renal disease.
    Gluba A; Mikhailidis DP; Lip GY; Hannam S; Rysz J; Banach M
    Int J Cardiol; 2013 Apr; 164(2):141-50. PubMed ID: 22305775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome and chronic kidney disease.
    Guarnieri G; Zanetti M; Vinci P; Cattin MR; Pirulli A; Barazzoni R
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S19-23. PubMed ID: 20797564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
    Chalmers L; Kaskel FJ; Bamgbola O
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):352-64. PubMed ID: 17045221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal manifestations in the metabolic syndrome.
    Locatelli F; Pozzoni P; Del Vecchio L
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S81-5. PubMed ID: 16565254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and chronic kidney disease.
    Ruan X; Guan Y
    J Diabetes; 2009 Dec; 1(4):236-45. PubMed ID: 20923524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of insulin resistance using surrogate markers in patients of metabolic syndrome.
    Bhatnagar MK; Arora S; Singh V; Bhattacharjee J
    Diabetes Metab Syndr; 2011; 5(1):29-32. PubMed ID: 22814838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and metabolic syndrome: potential benefit from specific nutritional components.
    Abete I; Goyenechea E; Zulet MA; Martínez JA
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21 Suppl 2():B1-15. PubMed ID: 21764273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome.
    Carbone F; Montecucco F; Mach F; Pontremoli R; Viazzi F
    Thromb Haemost; 2013 Nov; 110(5):940-58. PubMed ID: 23966104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases.
    Rüster C; Wolf G
    Semin Nephrol; 2013 Jan; 33(1):44-53. PubMed ID: 23374893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic syndrome: definitions, prevalence and management.
    Levesque J; Lamarche B
    J Nutrigenet Nutrigenomics; 2008; 1(3):100-8. PubMed ID: 19776619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management.
    Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
    Nutr Metab Cardiovasc Dis; 2010 Feb; 20(2):140-6. PubMed ID: 19833491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study.
    Xu A; Tso AW; Cheung BM; Wang Y; Wat NM; Fong CH; Yeung DC; Janus ED; Sham PC; Lam KS
    Circulation; 2007 Mar; 115(12):1537-43. PubMed ID: 17389279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome and target organ damage: role of blood pressure.
    Cuspidi C; Sala C; Zanchetti A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):731-43. PubMed ID: 18510489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of the modified ATP III defined metabolic syndrome and severe obesity as predictors of insulin resistance in overweight children and adolescents: a cross-sectional study.
    Dhuper S; Cohen HW; Daniel J; Gumidyala P; Agarwalla V; St Victor R; Dhuper S
    Cardiovasc Diabetol; 2007 Feb; 6():4. PubMed ID: 17300718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes.
    Utzschneider KM; Van de Lagemaat A; Faulenbach MV; Goedecke JH; Carr DB; Boyko EJ; Fujimoto WY; Kahn SE
    Obesity (Silver Spring); 2010 Sep; 18(9):1781-7. PubMed ID: 20379148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men.
    Onat A; Hergenç G; Can G; Küçükdurmaz Z
    Obesity (Silver Spring); 2009 Mar; 17(3):564-70. PubMed ID: 19238142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARs and the kidney in metabolic syndrome.
    Ruan X; Zheng F; Guan Y
    Am J Physiol Renal Physiol; 2008 May; 294(5):F1032-47. PubMed ID: 18234957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy.
    Cordero A; Laclaustra M; León M; Grima A; Casasnovas JA; Luengo E; del Rio A; Ferreira I; Alegria E
    Am J Hypertens; 2006 Feb; 19(2):189-96; discussion 197-8. PubMed ID: 16448891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.